<DOC>
	<DOCNO>NCT02183155</DOCNO>
	<brief_summary>The primary purpose study evaluate effect meloxicam tablet ( 7.5 , 15 mg 30 mg ) meloxicam placebo . Extended-release indomethacin capsule ( 75 mg ) active control assess trial sensitivity bleeding time healthy subject . The secondary aim study assess effect treatment platelet function coagulation parameter .</brief_summary>
	<brief_title>Effect Meloxicam Tablets Bleeding Time Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Healthy male female subject age 18 55 year Negative urine pregnancy test Day1 females childbearing potential Weight within +/ 20 percent ideal weight accord Metropolitan Life Height Weight chart Willing able cooperate investigator his/her staff Written inform consent accordance GCP ( Good Clinical Practice ) local legislation Any finding , medical condition dietary restriction , investigator 's opinion , may interfere optimal participation study produce significant risk subject In opinion investigator , subject disease condition may result altered absorption , excess accumulation , impaired metabolism excretion trial medication A know suspected hypersensitivity trial medication excipients NSAIDs ( NonSteroid AntiInflammatory Drug ) A history gastrointestinal ulcer , perforation bleed A history cerebrovascular bleed bleed disorder Women childbearing potential use adequate contraception ( e.g , intrauterine device , contraceptive pill , DepoProvera® implant , barrier device ) least 3 month prior , duration trial participation . It note NSAIDs may interfere effectiveness intrauterine device History bronchial asthma Use medication might influence result trial Use anticoagulant , include warfarin , heparin , ticlopidine , clopidogrel aspirin Any laboratory value outside normal range consider clinically significant investigator . In addition , subject follow specific laboratory value allow : A serum creatinine concentration baseline &gt; 1.5 mg/dl SGOT ( serum glutamicoxaloacetic transaminase ) SGPT ( serum glutamicpyruvic transaminase ) liver enzymes result baseline &gt; 1.5 time upper limit normal A hemoglobin concentration &lt; 10.5 g/dl A white cell count &lt; 3500/mm³ A platelet &lt; 100,000/mm³ document abnormal bleeding time , platelet aggregation , thromboxane B2 synthesis , thromboplastin time ( PT ) activate partial thromboplastin time ( APTT ) Inability refrain smoke test day Participation another trial investigational drug within 30 day enter trial Subjects increase keloid formation Previous surgery gastrointestinal tract ( except appendectomy ) Participation excessive physical activity ( ≤ 5 day prior administration ) Current drug alcohol abuse Small difficult locate arm vein would impair clinician 's ability draw blood sample Homeopathic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>